antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-500Research ArticleОБЗОРЫREVIEWSДискордантность статуса эстрогеновыгх рецепторов между первичным и метастатическим раком молочной железы - возможные причины и прогностическая значимостьDiscordance of Estrogen Receptor Status Between Primary and Metastatic Breast Cancer: Possible Reasons and Prognostic ValueБогушТ. А.BogushT. A.noemail@neicon.ruПоповаА. С.PopovaA. S.noemail@neicon.ruДудкоЕ. А.DudkoE. A.noemail@neicon.ruИгнатоваЕ. О.IgnatovaE. O.noemail@neicon.ruПолоцкийБ. Е.PolotskyB. E.noemail@neicon.ruТюляндинС. А.TjuljandinS. A.noemail@neicon.ruДавыдовМ. И.DavydovM. I.noemail@neicon.ruФедеральное государственное бюджетное учреждение «Российский онкологический научный центр им. Н.Н. Блохина» Российской академии медицинских наукРоссияN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesRussian FederationМГУ им. М.В. ЛомоносоваРоссияM.V. Lomonosov Moscow State UniversityRussian Federation201313052020587-84047Copyright © Богуш Т.А., Попова А.С., Дудко Е.А., Игнатова Е.О., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И., 20202020Богуш Т.А., Попова А.С., Дудко Е.А., Игнатова Е.О., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И.Bogush T.A., Popova A.S., Dudko E.A., Ignatova E.O., Polotsky B.E., Tjuljandin S.A., Davydov M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/500

Целью данного обзора явилась систематизация сведений о дискордантности экспрессии эстрогеновых рецепторов в первичном и метастатическом раке молочной железы, в разных метастазах, при повторных анализах одной и той же ткани. Обсуждаются возможные причины этого феномена. Авторы подчеркивают необходимость проведения анализа эстрогеновых рецепторов в метастазах рака молочной железы, независимо от рецепторного статуса первичной опухоли, для прогнозирования течения метастатической болезни и адекватного лечения метастатической опухоли в строгом соответствии с её рецепторным статусом на момент лекарственной терапии. Проанализированы работы, цитированные в поисковой системе Pub Med до мая 2013 года.

The aim of the review was systematization of the data on discordance in expression of estrogen receptors between primary and metastatic breast cancer, different metastases and repeated analyses of the same tissue. The possible reasons for the phenomenon are discussed. The authors emphasize the need to analyze estrogen receptors in breast cancer metastases, regardless of the receptor status of the primary tumor, for predicting the course of the metastatic disease and providing an adequate treatment of the metastatic tumor in strict accordance with its receptor status during drug therapy. The works cited in the search engine Pub Med to May 2013 were analyzed.

дискордантностьэстрогеновые рецепторырак молочной железыметастазы рака молочной железыпрогнозтерапияdiscordanceestrogen receptorsbreast cancermetastatic breast cancerprognosistherapyReferencesIguchi C., Nio Y., Itakura M. Heterogenic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. J Surg Oncol 2003; 83: 2: 85-93.Iguchi C., Nio Y., Itakura M. Heterogenic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome. J Surg Oncol 2003; 83: 2: 85-93.Gong Y., Han E.Y., Guo M. et al. Stability of estrogen receptor status in breast carcinoma. Cancer 2011; 117: 4: 705-713.Gong Y., Han E.Y., Guo M. et al. Stability of estrogen receptor status in breast carcinoma. Cancer 2011; 117: 4: 705-713.Rosen P.P., Menendez-Botet C.J., Urban J.A. et al. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 1977; 39: 5: 2194-2200.Rosen P.P., Menendez-Botet C.J., Urban J.A. et al. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 1977; 39: 5: 2194-2200.Hammond M.E.H., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (Unabridged Version). Arch Pathol Lab Med 2010; 134: 7: e48-e72.Hammond M.E.H., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (Unabridged Version). Arch Pathol Lab Med 2010; 134: 7: e48-e72.Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 5: 1474-1474.Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 5: 1474-1474.Hoehn J.L., Plotka E.D., Dickson K.B. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg 1979; 190: 1: 69-71.Hoehn J.L., Plotka E.D., Dickson K.B. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg 1979; 190: 1: 69-71.Lee Y.-T. Variability of steroid receptors in multiple biopsies of breast cancer: effect of systemic therapy. Breast Cancer Res Treat 1982; 2: 2: 185-193.Lee Y.-T. Variability of steroid receptors in multiple biopsies of breast cancer: effect of systemic therapy. Breast Cancer Res Treat 1982; 2: 2: 185-193.Holdaway I.M., Bowditch J.V. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 3: 479-485.Holdaway I.M., Bowditch J.V. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 3: 479-485.Raemaekers J.M., Beex L.V., Koenders A.J. et al. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 1984; 20: 8: 1011-1018.Raemaekers J.M., Beex L.V., Koenders A.J. et al. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 1984; 20: 8: 1011-1018.Li B. D.L., Byskosh A., Duda R.B., Molteni A. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57: 2: 71-77.Li B. D.L., Byskosh A., Duda R.B., Molteni A. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57: 2: 71-77.Shimizu C., Fukutomi T., Tsuda H. et al. C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000; 73: 1: 17-20.Shimizu C., Fukutomi T., Tsuda H. et al. C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000; 73: 1: 17-20.Kamby C., Rasmussen B.B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 2: 252-257.Kamby C., Rasmussen B.B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 2: 252-257.Hoefnagel L., van de Vijver M., van Slooten H.-J. et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12: 5: R75.Hoefnagel L., van de Vijver M., van Slooten H.-J. et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12: 5: R75.Bogina G., Bortesi L., Marconi M. et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011; 459: 1: 1-10.Bogina G., Bortesi L., Marconi M. et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011; 459: 1: 1-10.Sari E., Guler G., Hayran M. et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011; 28: 1: 57-63.Sari E., Guler G., Hayran M. et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011; 28: 1: 57-63.Botteri E., Disalvatore D., Curigliano G. et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012; 21: 3: 284-288.Botteri E., Disalvatore D., Curigliano G. et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012; 21: 3: 284-288.Jensen J., Knoop A., Ewertz M., Laenkholm A.-V. ER, HER2, and TOP 2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012; 132: 2: 511-521.Jensen J., Knoop A., Ewertz M., Laenkholm A.-V. ER, HER2, and TOP 2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012; 132: 2: 511-521.Amir E., Miller N., Geddie W. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 6: 587-592.Amir E., Miller N., Geddie W. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 6: 587-592.Romain P.St., Madan R., Tawfik O.W. et al. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012; 43: 3: 398-404.Romain P.St., Madan R., Tawfik O.W. et al. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012; 43: 3: 398-404.Lower E., Glass E., Bradley D. et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90: 1: 65-70.Lower E., Glass E., Bradley D. et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90: 1: 65-70.Guarneri V., Giovannelli S., Ficarra G. et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 8: 838-844.Guarneri V., Giovannelli S., Ficarra G. et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 8: 838-844.Amir E., Ooi W.S., Simmons C. et al. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008; 20: 10: 763-768.Amir E., Ooi W.S., Simmons C. et al. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008; 20: 10: 763-768.Idirisinghe P.K.A., Thike A.A., Cheok P.Y. et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer: pathologic correlations and clinical significance. Am J Clin Pathol 2010; 133: 3: 416-429.Idirisinghe P.K.A., Thike A.A., Cheok P.Y. et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer: pathologic correlations and clinical significance. Am J Clin Pathol 2010; 133: 3: 416-429.Falck A.-K., Fernö M., Bendahl P.-O., Rydén L. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 2010; 34: 7: 1434-1441.Falck A.-K., Fernö M., Bendahl P.-O., Rydén L. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 2010; 34: 7: 1434-1441.Hilton J.F., Amir E., Hopkins S. et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat 2011; 129: 3: 761-765.Hilton J.F., Amir E., Hopkins S. et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat 2011; 129: 3: 761-765.Nishimura R., Osako T., Okumura Y. et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011; 9: 131. doi: 10.1186/1477-7819-9-131Nishimura R., Osako T., Okumura Y. et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011; 9: 131. doi: 10.1186/1477-7819-9-131Ibrahim T., Farolfi A., Scarpi E. et al. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical Impact Oncology 2013; 84: 3: 150-157.Ibrahim T., Farolfi A., Scarpi E. et al. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical Impact Oncology 2013; 84: 3: 150-157.Dieci M.V., Barbieri E., Piacentini F. et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 2013; 24: 1: 101-108.Dieci M.V., Barbieri E., Piacentini F. et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 2013; 24: 1: 101-108.Lindström L.S., Karlsson E., Wilking U.M. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 21: 2601-2608.Lindström L.S., Karlsson E., Wilking U.M. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 21: 2601-2608.Thompson A., Jordan L., Quinlan P. et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res 2010; 12: 6: R92.Thompson A., Jordan L., Quinlan P. et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res 2010; 12: 6: R92.Koo J.S., Jung W., Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010; 96: 3: 424-432.Koo J.S., Jung W., Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010; 96: 3: 424-432.Dabbs D.J., Landreneau R.J., Liu Y. et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 2: 403-406.Dabbs D.J., Landreneau R.J., Liu Y. et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 2: 403-406.Raso M.G., Behrens C., Herynk M.H. et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15: 17: 5359-5368.Raso M.G., Behrens C., Herynk M.H. et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15: 17: 5359-5368.Huang Z., Zhu W., Szekeres G., Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol 2005; 13: 1: 91-95.Huang Z., Zhu W., Szekeres G., Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol 2005; 13: 1: 91-95.Gomez-Fernandez C., Daneshbod Y., Nassiri M. et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol 2008; 130: 6: 879-882.Gomez-Fernandez C., Daneshbod Y., Nassiri M. et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol 2008; 130: 6: 879-882.Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Количественная иммунофлуоресцентная оценка с использованием проточной цитофлуориметрии экспрессии эстрогеновых рецепторов в в солидных опухолях человека. Вестн. Моск ун-та Сер. 2. Химия 2011; 52: 4: 305-312.Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Количественная иммунофлуоресцентная оценка с использованием проточной цитофлуориметрии экспрессии эстрогеновых рецепторов в в солидных опухолях человека. Вестн. Моск ун-та Сер. 2. Химия 2011; 52: 4: 305-312.Богуш Т.А., Тихомиров М.В., Дудко Е.А. и др. Количественное иммунофлуоресцентное определение экспрессии Pgp в солидных опухолях человека с использованием метода проточной цитофлуориметрии. Вестн. Моск ун-та 2012; 53: 3: 207-215.Богуш Т.А., Тихомиров М.В., Дудко Е.А. и др. Количественное иммунофлуоресцентное определение экспрессии Pgp в солидных опухолях человека с использованием метода проточной цитофлуориметрии. Вестн. Моск ун-та 2012; 53: 3: 207-215.Jakobsen J.N., Santoni-Rugiu E., Ravn J., Sorensen J.B. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer 2013; 49: 11: 2494-2503.Jakobsen J.N., Santoni-Rugiu E., Ravn J., Sorensen J.B. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer 2013; 49: 11: 2494-2503.Umekita Y., Sagara Y., Yoshida H. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res 1998; 89: 1: 27-32.Umekita Y., Sagara Y., Yoshida H. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res 1998; 89: 1: 27-32.Allegra J.C., Barlock A., Huff K.K., Lippman M.E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 4: 792-794.Allegra J.C., Barlock A., Huff K.K., Lippman M.E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 4: 792-794.Johnston S.R.D., Saccani-Jotti G., Smith I.E. et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 15: 3331-3338.Johnston S.R.D., Saccani-Jotti G., Smith I.E. et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 15: 3331-3338.Macfarlane R, Seal M., Speers C. et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012; 17: 2: 172-178.Macfarlane R, Seal M., Speers C. et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012; 17: 2: 172-178.Friboulet L., Olaussen K.A., Pignon J.-P. et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 12: 1101-1110.Friboulet L., Olaussen K.A., Pignon J.-P. et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 12: 1101-1110.

The authors declare that there are no conflicts of interest present.